Table 2 Patients characteristics
Characteristic | Training cohort | Validation cohort | PÂ value |
|---|---|---|---|
n = 227 (%) | n = 113 (%) | ||
Sex | Â | Â | 0.659 |
 Male | 186 (81.9) | 90 (79.6) |  |
 Female | 41 (18.1) | 23 (20.4) |  |
Age (y) |  |  |  > 0.999 |
 Median (range) | 59 (28–79) | 58 (31–81) |  |
ECOG score | Â | Â | 0.126 |
 0 | 29 (12.8) | 16 (14.2) |  |
 1 | 170 (74.9) | 91 (80.5) |  |
 2 | 28 (12.3) | 6 (5.3) |  |
Weight loss ≥ 5 kg |  |  | 0.153 |
 Yes | 23 (10.1) | 6 (5.3) |  |
 No | 204 (89.9) | 107 (94.7) |  |
Smoke index ≥ 400 |  |  | 0.298 |
 Yes | 129 (56.8) | 57 (50.4) |  |
 No | 98 (43.2) | 56 (49.6) |  |
Pathological types | Â | Â | 0.627 |
 Squamous cell carcinoma | 130 (57.3) | 65 (57.5) |  |
 Adenocarcinoma | 80 (35.3) | 41 (36.3) |  |
 Lymphoepithelioma-like carcinoma | 10 (4.4) | 5 (4.4) |  |
 Adenosquamous carcinoma | 1 (0.4) | 1 (0.9) |  |
 Adenoid cystic carcinoma | 2 (0.9) | 0 (0) |  |
 Large cell neuroendocrine carcinoma | 0 (0) | 1 (0.9) |  |
 Giant cell carcinoma | 1 (0.4) | 0 (0) |  |
 Not otherwise specified(NOS) | 3 (1.3) | 0 (0) |  |
GTV (cm3) |  |  |  > 0.999 |
 Median(range) | 100.6 (9.1–664.3) | 101.3 (10.5–567.7) |  |
GTV risk group | Â | Â | 0.993 |
 I (< 70 cm3) | 65 (28.6) | 32 (28.3) |  |
 II (70–180 cm3) | 119 (52.4) | 60 (53.1) |  |
 III (> 180 cm3) | 43 (19.0) | 21 (18.6) |  |
TNM stage | Â | Â | 0.978 |
 IIIA | 65 (28.6) | 32 (28.3) |  |
 IIIB | 114 (50.2) | 58 (51.3) |  |
 IIIC | 48 (21.2) | 23 (20.4) |  |
Neoadjuvant chemotherapy | Â | Â | 0.358 |
 Yes | 166 (73.1) | 88 (77.9) |  |
 No | 61 (26.9) | 25 (22.1) |  |
Adjuvant chemotherapy | Â | Â | 0.127 |
 Yes | 55 (24.2) | 19 (16.8) |  |
 No | 172 (75.8) | 94 (83.2) |  |